Warner Chilcott waives exclusivity; Barr to market generic Ovcon

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Barr Pharmaceuticals, Inc. said Warner Chilcott Ltd. waived the exclusivity provision of the license for Barr's generic version of Warner Chilcott's Ovcon 35 Tablets oral contraceptive, paving the way for Barr Laboratories, Inc. to launch its generic Ovcon 35 oral contraceptive under the trade name Balziva.

"Following the launch of our Balziva product in October, we will manufacture and market a generic oral contraceptive portfolio that is the largest in the industry, totaling 24 products," Barr chief executive officer and chairman Bruce L. Downey said in a news release.

Barr had been manufacturing Ovcon 35 for Warner Chilcott under a related supply agreement but believes those product orders will stop.

Ovcon 35 had annual sales of about $95 million for the 12 months ended July 2006.

Barr Laboratories is a pharmaceutical company based in Woodcliff Lake, N.J.

Warner Chilcott is a specialty pharmaceutical company based in Millbrook, Northern Ireland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.